These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 30916448)

  • 1. Prevalence of cognitive impairment in patients with substance use disorder.
    Bruijnen CJWH; Dijkstra BAG; Walvoort SJW; Markus W; VanDerNagel JEL; Kessels RPC; DE Jong CAJ
    Drug Alcohol Rev; 2019 May; 38(4):435-442. PubMed ID: 30916448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Which psychiatric comorbidities in cannabis dependence during adolescence? Comparison of outpatients and controls].
    Dorard G; Bungener C; Phan O; Edel Y; Corcos M; Berthoz S
    Encephale; 2018 Feb; 44(1):2-8. PubMed ID: 27637871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Sociodemographic profiles, addictive and mental comorbidity in cannabis users in an outpatient specific setting].
    Guillem E; Pelissolo A; Vorspan F; Bouchez-Arbabzadeh S; Lépine JP
    Encephale; 2009 Jun; 35(3):226-33. PubMed ID: 19540408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of cohort substance use upon likelihood of transitioning through stages of alcohol and cannabis use and use disorder: Findings from the Australian National Survey on Mental Health and Wellbeing.
    Degenhardt L; Glantz M; Bharat C; Peacock A; Lago L; Sampson N; Kessler RC
    Drug Alcohol Rev; 2018 May; 37(4):546-556. PubMed ID: 29505682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the prevalence of substance-induced neurocognitive disorder among polysubstance users, adding subjective and objective evidence of cognitive impairment.
    Toledo-Fernández A; Marín-Navarrete R; Villalobos-Gallegos L; Salvador-Cruz J; Benjet C; Roncero C
    Psychiatry Res; 2020 Jun; 288():112944. PubMed ID: 32339804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of comorbid substance use on neuropsychological performance in subjects with psychotic or mood disorders].
    Liraud F; Verdoux H
    Encephale; 2002; 28(2):160-8. PubMed ID: 11972143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cannabis and schizophrenia: demographic and clinical correlates].
    Dervaux A; Laqueille X; Bourdel MC; Leborgne MH; Olié JP; Lôo H; Krebs MO
    Encephale; 2003; 29(1):11-7. PubMed ID: 12640322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of substance abuse among patients in general medical facilities in Kenya.
    Ndetei DM; Khasakhala LI; Ongecha-Owuor FA; Kuria MW; Mutiso V; Kokonya DA
    Subst Abus; 2009; 30(2):182-90. PubMed ID: 19347756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prevalence and characteristics of moderate- to high-risk regulated and unregulated substance use among patients admitted to four public hospitals in Tshwane, South Africa.
    Scheibe AP; Gloeck NR; Shelly S; Marcus TS; Hugo J
    S Afr Med J; 2019 Nov; 109(12):971-977. PubMed ID: 31865961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comorbidity in 207 cannabis users in a specific outpatient setting].
    Guillem E; Arbabzadeh-Bouchez S; Vorspan F; Bellivier F
    Encephale; 2015 Jun; 41 Suppl 1():S7-12. PubMed ID: 25123065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Common substance use disorders in older adults.
    Seim L; Vijapura P; Pagali S; Burton MC
    Hosp Pract (1995); 2020 Mar; 48(sup1):48-55. PubMed ID: 32073917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conditional probabilities of substance use disorders and associated risk factors: Progression from first use to use disorder on alcohol, cannabis, stimulants, sedatives and opioids.
    Marel C; Sunderland M; Mills KL; Slade T; Teesson M; Chapman C
    Drug Alcohol Depend; 2019 Jan; 194():136-142. PubMed ID: 30439610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive Impairment and Tramadol Dependence.
    Bassiony MM; Youssef UM; Hassan MS; Salah El-Deen GM; El-Gohari H; Abdelghani M; Abdalla A; Ibrahim DH
    J Clin Psychopharmacol; 2017 Feb; 37(1):61-66. PubMed ID: 27918316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of substance use and psychiatric disorders in a highly select chronic pain population.
    Proctor SL; Estroff TW; Empting LD; Shearer-Williams S; Hoffmann NG
    J Addict Med; 2013; 7(1):17-24. PubMed ID: 23131838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attention deficit hyperactivity disorder, other mental health problems, substance use, and driving: examination of a population-based, representative canadian sample.
    Vingilis E; Mann RE; Erickson P; Toplak M; Kolla NJ; Seeley J; Jain U
    Traffic Inj Prev; 2014; 15 Suppl 1():S1-9. PubMed ID: 25307372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Working memory impairment in cannabis- and opioid-dependent adolescents.
    Vo HT; Schacht R; Mintzer M; Fishman M
    Subst Abus; 2014; 35(4):387-90. PubMed ID: 25148203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Montreal Cognitive Assessment (MoCA) is Sensitive to Head Injury and Cognitive Impairment in a Residential Alcohol and Other Drug Therapeutic Community.
    Marceau EM; Lunn J; Berry J; Kelly PJ; Solowij N
    J Subst Abuse Treat; 2016 Jul; 66():30-6. PubMed ID: 27211994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relation between gray matter volume and the use of alcohol, tobacco, cocaine and cannabis in male polysubstance users.
    Kaag AM; Schulte MHJ; Jansen JM; van Wingen G; Homberg J; van den Brink W; Wiers RW; Schmaal L; Goudriaan AE; Reneman L
    Drug Alcohol Depend; 2018 Jun; 187():186-194. PubMed ID: 29679913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Relation Between ADHD Medication and Mild Cognitive Impairment, as Assessed by the Montreal Cognitive Assessment (MoCA), in Patients Entering Substance Use Disorder Inpatient Treatment.
    Helene Bergly T; Julius Sømhovd M
    J Dual Diagn; 2018; 14(4):228-236. PubMed ID: 30183548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cannabis cessation interventions offered to young French users: predictors of follow-up].
    Abdoul H; Le Faou AL; Bouchez J; Touzeau D; Lagrue G
    Encephale; 2012 Apr; 38(2):141-8. PubMed ID: 22516272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.